share_log

Johnson & Johnson | 4: Statement of changes in beneficial ownership of securities-Officer REED JOHN C

Johnson & Johnson | 4: Statement of changes in beneficial ownership of securities-Officer REED JOHN C

强生 | 4：持股变动声明-高管 REED JOHN C
美股sec公告 ·  05/03 16:37
Moomoo AI 已提取核心信息
On May 1, 2024, John C. Reed, EVP of Innovative Medicine, R&D at Johnson & Johnson, completed a stock transaction involving the company's common stock. Reed executed a sale of 10,984 shares at a price of $144.59 per share, resulting in a total transaction value of $1,588,176.56. Prior to this sale, Reed acquired 22,255 shares through the exercise of derivative securities at no cost. Following these transactions, Reed's direct holdings in Johnson & Johnson common stock amounted to 11,577 shares.
On May 1, 2024, John C. Reed, EVP of Innovative Medicine, R&D at Johnson & Johnson, completed a stock transaction involving the company's common stock. Reed executed a sale of 10,984 shares at a price of $144.59 per share, resulting in a total transaction value of $1,588,176.56. Prior to this sale, Reed acquired 22,255 shares through the exercise of derivative securities at no cost. Following these transactions, Reed's direct holdings in Johnson & Johnson common stock amounted to 11,577 shares.
2024年5月1日，强生公司创新医学研发执行副总裁约翰·里德完成了一项涉及公司普通股的股票交易。里德以每股144.59美元的价格出售了10,984股股票，总交易价值为1,588,176.56美元。在此次出售之前，里德通过行使衍生证券免费收购了22,255股股票。这些交易之后，里德直接持有的强生普通股为11,577股。
2024年5月1日，强生公司创新医学研发执行副总裁约翰·里德完成了一项涉及公司普通股的股票交易。里德以每股144.59美元的价格出售了10,984股股票，总交易价值为1,588,176.56美元。在此次出售之前，里德通过行使衍生证券免费收购了22,255股股票。这些交易之后，里德直接持有的强生普通股为11,577股。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息